Literature DB >> 24900032

Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study.

Jai Hyuen Lee1, Won Ae Lee2, Seok Gun Park1, Dong Kook Park3, Hwan Namgung3.   

Abstract

PURPOSE: The clinical availability of 2-deoxy-2-[18F] fluoro-D-glucose (FDG) dual-time point positron emission tomography/computerized tomography (DTPP) has been investigated in diverse oncologic fields. The aim of this preliminary study was to evaluate the relationship between various immunohistopathologic markers reflecting disease progression of colorectal cancer and parameters extracted from FDG DTPP in colorectal cancer patients.
MATERIALS AND METHODS: Forty-seven patients with histologically confirmed colorectal cancer were analyzed in this preliminary study. FDG DTPP consisted of an early scan 1 h after FDG injection and a delayed scan 1.5 h after the early scan. Based on an analysis of FDG DTPP, we estimated the maximum standardized uptake value (SUV) of tumors on the early and delayed scans (SUVearly and SUVdelayed, respectively). The retention index (RI) was calculated as follows: (SUVdelayed - SUVearly) × 100/ SUVearly. The clinicopathological findings (size and T and N stages) and immunohistochemical factors [glucose transporter 1 (GLUT-1), hexokinase 2 (HK-2), p53, P504S, and β-catenin] were analyzed by visual analysis.
RESULTS: The RIs calculated from the SUVs ranged from -1.8 to 73.4 (31.8 ± 15.5). The RIs were significantly higher in patients with high T stages (T3 and T4) than with low T stages (T1 and T2; p < 0.05). Among the immunohistochemical analytic markers, GLUT-1 had the highest positive staining rate (93.6%) compared to other markers. Based on univariable analysis, it was shown that the RI of high-level GLUT-1 expression was significantly higher than low-level GLUT-1 expression (p = 0.01), and the RI of high-level p53 expression was slightly higher than low-level p53 expression (p = 0.08). Multivariate analysis to investigate a link between RI and clinicopathologic parameters of colorectal carcinoma showed that GLUT-1, p53, and T staging were independently connected with increased RIs (p < 0.05, total) using backward selection methods. There was no significant statistical relationship between SUVearly and SUVdelayed and clinicopathologic parameters in this study.
CONCLUSION: The RIs obtained from preoperative colorectal cancers had a significant relationship to tumor size, T staging, GLUT-1, and p53, in contrast to SUVearly or SUVdelayed. Compared with previous reports, our results showed that RI can better predict GLUT-1 expression than HK-2 and other immunohistochemical markers. This study demonstrated that the RI might have the potential to be applied as a prognostic marker in preoperative colorectal cancer.

Entities:  

Keywords:  Colorectal cancer; Dual-time point imaging; FDG PET; Glucose transporter; Hexokinase

Year:  2012        PMID: 24900032      PMCID: PMC4042981          DOI: 10.1007/s13139-011-0120-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  33 in total

1.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.

Authors:  R Hustinx; R J Smith; F Benard; D I Rosenthal; M Machtay; L A Farber; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-10

2.  p53 mutation found to be a significant prognostic indicator in distal colorectal cancer.

Authors:  R Okubo; H Masuda; N Nemoto
Journal:  Oncol Rep       Date:  2001 May-Jun       Impact factor: 3.906

3.  Prognostic implication of dual-phase PET in adenocarcinoma of the lung.

Authors:  Mohamed Houseni; Wichana Chamroonrat; Jiyuan Zhuang; Rohit Gopal; Abass Alavi; Hongming Zhuang
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

4.  Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer.

Authors:  Bal Sanghera; Wai Lup Wong; Martin A Lodge; Sharon Hain; David Stott; John Lowe; Catherine Lemon; Kate Goodchild; Michele Saunders
Journal:  Nucl Med Commun       Date:  2005-10       Impact factor: 1.690

5.  Prognostic significance of beta-catenin in colorectal cancer with liver metastasis.

Authors:  S A Han; H Chun; C M Park; S J Kang; S H Kim; D Sohn; S H Yun; W Y Lee
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-12       Impact factor: 4.126

6.  Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer.

Authors:  Sze Chuen Cesar Wong; Elena Siu Fong Lo; King Chung Lee; John K C Chan; W L Wendy Hsiao
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

7.  (18)F-FDG PET analysis of schwannoma: increase of SUVmax in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors.

Authors:  Kenichiro Hamada; Yasuhiko Tomita; Ying Qiu; Miki Tomoeda; Takafumi Ueda; Noriyuki Tamai; Nobuyuki Hashimoto; Hideki Yoshikawa; Katsuyuki Aozasa; Jun Hatazawa
Journal:  Skeletal Radiol       Date:  2008-12-17       Impact factor: 2.199

8.  Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.

Authors:  Daisuke Uesaka; Yoshiki Demura; Takeshi Ishizaki; Shingo Ameshima; Isamu Miyamori; Masato Sasaki; Yasuhisa Fujibayashi; Hidehiko Okazawa
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

9.  Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis.

Authors:  Senqing Chen; Juying Liu; Guimei Li; Fugen Mo; Xinyu Xu; Tong Zhang; Xiaomei Zhang; Jintian Li; Xiao Han; Yujie Sun
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

10.  GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.

Authors:  R S Haber; A Rathan; K R Weiser; A Pritsker; S H Itzkowitz; C Bodian; G Slater; A Weiss; D E Burstein
Journal:  Cancer       Date:  1998-07-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.